Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

Nima Mowzoon, Alyssa Sussman, Walter G Bradley

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

We report favorable results of the long term use of mycophenolate in the treatment of three patients with myasthenia gravis (MG), two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), one patient with secondary polymyositis (PM), and one patient with inclusion body myositis (IBM). Side effects were mild. Mycophenolate appears to be a useful addition to the armamentarium of immunosuppressants for treatment of chronic immunologically mediated neuromuscular diseases.

Original languageEnglish
Pages (from-to)119-122
Number of pages4
JournalJournal of the Neurological Sciences
Volume185
Issue number2
DOIs
StatePublished - Apr 1 2001

Fingerprint

Inclusion Body Myositis
Mycophenolic Acid
Polyneuropathies
Myasthenia Gravis
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polymyositis
Neuromuscular Diseases
Therapeutics
Immunosuppressive Agents

Keywords

  • Chronic inflammatory demyelinating polyneuropathy
  • Inclusion body myositis
  • Myasthenia gravis
  • Mycophenolate
  • Polymyositis
  • Therapy

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. / Mowzoon, Nima; Sussman, Alyssa; Bradley, Walter G.

In: Journal of the Neurological Sciences, Vol. 185, No. 2, 01.04.2001, p. 119-122.

Research output: Contribution to journalArticle

@article{c36aac9314ad4f51a996d06a65e4ac1e,
title = "Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis",
abstract = "We report favorable results of the long term use of mycophenolate in the treatment of three patients with myasthenia gravis (MG), two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), one patient with secondary polymyositis (PM), and one patient with inclusion body myositis (IBM). Side effects were mild. Mycophenolate appears to be a useful addition to the armamentarium of immunosuppressants for treatment of chronic immunologically mediated neuromuscular diseases.",
keywords = "Chronic inflammatory demyelinating polyneuropathy, Inclusion body myositis, Myasthenia gravis, Mycophenolate, Polymyositis, Therapy",
author = "Nima Mowzoon and Alyssa Sussman and Bradley, {Walter G}",
year = "2001",
month = "4",
day = "1",
doi = "10.1016/S0022-510X(01)00478-6",
language = "English",
volume = "185",
pages = "119--122",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

AU - Mowzoon, Nima

AU - Sussman, Alyssa

AU - Bradley, Walter G

PY - 2001/4/1

Y1 - 2001/4/1

N2 - We report favorable results of the long term use of mycophenolate in the treatment of three patients with myasthenia gravis (MG), two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), one patient with secondary polymyositis (PM), and one patient with inclusion body myositis (IBM). Side effects were mild. Mycophenolate appears to be a useful addition to the armamentarium of immunosuppressants for treatment of chronic immunologically mediated neuromuscular diseases.

AB - We report favorable results of the long term use of mycophenolate in the treatment of three patients with myasthenia gravis (MG), two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), one patient with secondary polymyositis (PM), and one patient with inclusion body myositis (IBM). Side effects were mild. Mycophenolate appears to be a useful addition to the armamentarium of immunosuppressants for treatment of chronic immunologically mediated neuromuscular diseases.

KW - Chronic inflammatory demyelinating polyneuropathy

KW - Inclusion body myositis

KW - Myasthenia gravis

KW - Mycophenolate

KW - Polymyositis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0035310730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035310730&partnerID=8YFLogxK

U2 - 10.1016/S0022-510X(01)00478-6

DO - 10.1016/S0022-510X(01)00478-6

M3 - Article

C2 - 11311292

AN - SCOPUS:0035310730

VL - 185

SP - 119

EP - 122

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 2

ER -